American Society of Hirudotherapy

Diversity of hirudin and hirudin-like factor genes in the North-African medicinal leech, Hirudo troctina

Ahmed RB, Abilov A, Müller C (2024) · Parasitology Research · n=0

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidence

Study Profile

Design
molecular cloning and recombinant-expression analysis of 11 hirudin and hirudin-like factor (HLF) gene variants in the North-African medicinal leech Hirudo troctina (Tunisia, Germany collaboration; University of Tunis El Manar and University of Greifswald)
Sample size (n)
0
Intervention
Identification and molecular cloning of 11 hirudin/HLF variant genes from H. troctina; recombinant expression and purification of representative putative hirudin variants and HLFs followed by functional characterization for thrombin-inhibiting potencies
Comparator
Cross-species comparison with European Hirudo, Hirudinaria, and Whitmania hirudin/HLF gene sequences
Primary endpoint
Number and structural diversity of hirudin and HLF genes in H. troctina; thrombin-inhibitory activity of recombinant variants; phylogenetic placement of H. troctina factors
Primary result
Identified 11 hirudin/HLF variant genes in H. troctina - the highest diversity among European Hirudo species; three genes show recombination of exons/introns from different archetype genes; recombinant putative hirudin variants and HLF representatives showed measurable thrombin-inhibitory activity; phylogenetic analyses support early divergence of hirudins and HLFs in leech evolution
Follow-up duration
not applicable (gene-cloning and recombinant-protein mechanism study)
PMID
39540973

Key Findings

  • H. troctina genome contains 11 hirudin/HLF variant genes - the largest reported diversity among European Hirudo species
  • Three of the 11 genes appear to result from recombination of exons and introns from distinct archetype genes
  • Recombinant putative hirudin and HLF variants from H. troctina show measurable thrombin-inhibitory activity
  • Phylogenetic analyses support early divergence of hirudins and HLFs from a common ancestral gene
  • Adds North-African (Tunisian) medicinal leech data to the predominantly European-and-Asian molecular leech pharmacology base

Limitations

  • Mechanistic gene-cloning and recombinant-protein study only - no human or animal clinical outcomes
  • Thrombin-inhibition potencies characterized in vitro - in vivo bioavailability and clinical efficacy not assessed
  • Functional characterization limited to selected representative variants, not all 11 genes
  • Limited information on the natural expression levels and salivary release dynamics of each variant
  • Geographic scope limited to North Africa - generalizability of H. troctina pharmacology untested clinically

Clinical Implications

Ahmed 2024 expands the molecular pharmacology landscape of medicinal leeches by documenting that H. troctina contains an unusually rich repertoire of hirudin and hirudin-like factor (HLF) variant genes. For ASH editorial purposes, the trial supports the broader case that leech salivary pharmacology is highly diversified across geography and species, and motivates future research on H. troctina-derived therapeutics. The trial does not change clinical practice in the US (where Hirudo verbana is the principal commercial species) but does add mechanistic context for compound-registry pages on hirudin and related factors.

Related Trials

Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification

Merlino G, Carbone S, Servillo G, Marletta DA (2020)

Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial

Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)

Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review

Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction

Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)

← Back to RCT Library

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.